Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Published:2017-03-27 Issue:2 Volume:11 Page:229-238
ISSN:2095-0217
Container-title:Frontiers of Medicine
language:en
Short-container-title:Front. Med.

Author:

Lou Yinjun,Ma Yafang,Li Chenyin,Suo Sansan,Tong Hongyan,Qian Wenbin,Mai Wenyuan,Meng Haitao,Yu Wenjuan,Mao Liping,Wei Juyin,Xu Weilei,Jin Jie

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/article/10.1007/s11684-017-0506-y/fulltext.html

Reference26 articles.

1. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Insti-tute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/ Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109(8): 3189–3197

2. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, Di Nardo C, Wierda W, Jeanis V, O’Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 2015; 16(15): 1547–1555

3. Ravandi F, O’Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomepositive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116(12): 2070–2077

4. Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O’Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2015; 100(5): 653–661

5. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28(22): 3644–3652

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PASS‐ALL study of paediatric‐inspired versus adult chemotherapy regimens on survival of high‐risk Philadelphia‐negative B‐cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation;British Journal of Haematology;2023-12-05

2. Place of Allogeneic Hematopoietic Stem Cell Transplantation in the First Complete Remission in Ph-positive Acute Lymphoblastic Leukemia in Adults;The Scientific Notes of the Pavlov University;2023-08-29

3. Progress in the Treatment of Philadelphia Chromosome Positive Acute Lymphocytic Leukemia;Advances in Clinical Medicine;2023

4. Tyrosine kinase inhibitors and reduced-dose chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia;Hematology;2022-09-09

5. MRD in ALL: Optimization and Innovations;Current Hematologic Malignancy Reports;2022-05-26